secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001326732-23-000044
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor converts Genentech collaboration to royalty/milestone deal; up to $600M in milestones
--------------------------------------------------------------------------------

- New agreement replaces cost/profit-sharing with tiered royalties (low double-digit to mid-teens percent) starting June 1, 2024.
- Xencor eligible for up to $600M in milestones: $115M development, $185M regulatory, $300M sales-based.
- Genentech assumes sole responsibility for all clinical, regulatory, and commercial activities post-effective date.
- Original collaboration agreement remains in effect until May 31, 2024; Xencor had exercised royalty conversion option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/0001326732-23-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000044/xncr-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001326732-23-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer